Distinguished in WT1-Related Wilms Tumor Syndromes

Kristina Drott

Lund, M, SE 
Distinguished in WT1-Related Wilms Tumor Syndromes
Lund, M, SE 
OverviewLocationsClinical Research

Overview

Kristina Drott practices in Lund, Sweden. Ms. Drott is rated as a Distinguished expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Familial Wilms Tumor 2.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of WT1-Related Wilms Tumor Syndromes.

Gender
Female

Locations

Lund, M 22100, Sweden
Other Locations
Huddinge, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Combination product
Study Drugs: R-CHOEP, DA-EPOCH-R
Study Phase: Phase 2
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia
Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia
Enrollment Status: Completed
Publish Date: March 03, 2017
Intervention Type: Drug
Study Phase: Early Phase 1
View 1 Less Clinical Trial

17 Total Publications

Combined Immediate-Release and Extended-Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation.
Combined Immediate-Release and Extended-Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation.
Journal: Clinical pharmacology in drug development
Published: March 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Drott's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile